Skip to main content
. 2023 Aug 21;13(14):4711–4729. doi: 10.7150/thno.85663

Figure 3.

Figure 3

Biodistribution performed by ICP-MS in three animals per time point after retroorbital, intravenous injection of 300 mg kg-1 of either A) AGuIX-Bi (30Gd/70Bi) or B) AGuIX® in a NSCLC A549 murine model. C) Tumor-specific retention of nanoparticles varied with AGuIX® clearing as early as 1 h post-injection and AGuIX-Bi (30Gd/70Bi) maintaining sustained tumor nanoparticles for 24 h. Data is expressed as percent of the injected dose per gram of tissue (% ID g-1). D) Qualitative representations of A549 subcutaneous mice tumor accumulation as a function of time. Reconstructed MR images were bias field corrected. A red asterisk indicates a tumor and an orange arrow indicates a kidney. E) Quantitative measure of contrast enhancement following nanoparticle injection relative to surrounding healthy muscle tissue (n = 3). Data shown as mean ± SEM.